Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully ...

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to ...

Xeltis gains EU CE mark on positive trial data for vascular access graft

Approval for Xeltis’s aXess device was based on pivotal trial data that demonstrated 79% secondary patency and a patency ...
PharmaTimes

Xeltis prepares for commercial launch after strong aXess trial results

Xeltis has announced successful results from its aXess EU phase 3 trial, confirming the potential of its restorative vascular access conduit for patients undergoing hemodialysis. The multicentre study ...
The Stanford Daily

Axess preemptively crashes before spring registration

Axess, Stanford’s platform for accessing and recording students’ academic information, has crashed as of 9:00 p.m. on Sunday. The crash comes just two days before registration for spring quarter ...
Yahoo Finance

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization

EINDHOVEN, The Netherlands, April 21, 2026 (GLOBE NEWSWIRE)-- Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today ...